The transferred nuclear Overhauser effect has been used to determine the biologically active conformations of two stromelysin inhibitors. Both inhibitors used in this study were hydroxamic acids generated via chemical synthesis. These structures, representing the conformation of each inhibitor bound to stromelysin, superimposed with excellent agreement.
Stromelysin 1 is a zinc metalloendoproteinase that is secreted by synoviocytes and articular chondrocytes in response to inflammatory mediators such as interleukin 1 (1) . This enzyme is believed to cause the destruction of cartilage proteoglycans associated with osteo-and rheumatoid arthritis (2) . Stromelysin has also been implicated in the acceleration of procollagenase activation, thereby enhancing collagenase-induced cartilage degradation and contributing to the progression of the arthritic disease state (3) . Currently there are no therapies available to treat the cartilage degradation that occurs in these arthritic diseases. Because of the link of stromelysin to cartilage degradation, it is anticipated that the design of stromelysin inhibitors could result in the next major class of drugs for the treatment of arthritis.
Stromelysin is secreted from cells as a 55-to 57-kDa monomeric proenzyme that, upon activation, loses 80 amino acids to yield a 45-kDa mature enzyme. Recently a Cterminally truncated form of the proenzyme was reported. This 28-kDa protein has been shown to activate identically to the wild type, yielding a 19-kDa protein with binding properties very similar to full-length stromelysin (4, 5) . The threedimensional NMR structure of the inhibited catalytic domain of truncated human stromelysin 1 has been solved (6) ; however, to date the coordinates of these structures have not been released.
As part of a rational drug-design strategy, it is important to obtain structural knowledge of the enzyme-inhibitor complex. In particular, it is necessary to know the shape of the binding pocket, as well as the conformation of the interacting inhibitor. Most NMR methods that allow complete structure elucidation of an enzyme-inhibitor complex require significant amounts of enzyme as well as isotopic labeling of the enzyme or inhibitor (7, 8) . The transferred nuclear Overhauser effect (TR-NOE), however, provides a different approach that focuses on the conformation of the inhibitor in the bound state. This experiment involves the generation of cross-relaxation effects between two protons in the bound state that are subsequently transferred to the free state via chemical exchange (9) . The technique has an advantage over other NMR methods in that it does not require large amounts of enzyme or expensive isotopic labeling.
Here we report the enzyme-bound conformations of two stromelysin inhibitors, I-1 and I-2 in the hydroxamic acid series, which were obtained using the TR-NOE and twodimensional NMR spectroscopy (Fig. 1 ). These studies established the bound conformations of these compounds and provided information on the relative shape and orientation of the Si' and S2' binding pockets of stromelysin (10) . The NMR-derived structures were successfully used as templates in the design of three-dimensional data base search queries. Such structures may also be used as templates for the design of more potent inhibitors.
METHODS
Cloning, Expression, and Purification ofTruncated Recombinant Human Stromelysin. Truncated recombinant human stromelysin (28 kDa) was cloned, expressed, and isolated by modification of the procedure of Marcy et aL (4) . A 40-50% ammonium sulfate pellet of Escherichia coli cell extract from 10 liters of culture, grown to an OD of 0.8 at 600 nm, was dialyzed against 20 mM Tris/5 mM CaCl2/0.1 M NaCl (pH 8) and centrifuged. The resulting supernatant was then applied to a 2.5 x 21 cm column of QAE Sephadex (Pharmacia) in the above buffer. None of the stromelysin actvity, as determined by substance P assay (11) , bound to the column. The resulting pool (135 ml) was dialyzed against a buffer containing 20 mM 2-(N-morpholino)ethanesulfonic acid (Calbiochem), 5 mM CaCl2 (pH 6.5) The prewashed tube was subsequently charged with 2 ml of stromelysin solution and centrifuged as above. Additional deuterated buffer was added (-2 ml) to the concentrated enzyme. Centrifugation was continued for an additional 60 min. This procedure was repeated five times to yield a final 0.5-ml vol. A small aliquot (=50 ,ul) was tested for concentration and enzymatic activity. Final molar concentrations were 0.025-0.070 mM.
Preparation of Free Inhibitor. Inhibitors (hydroxamic acid I-1 or 1-2; -0.5 mg) were dissolved in 0.6 ml of deuterated buffer, p2H 7.6 before introduction to the NMR tube.
Preparation of Inhibitor/Stromelysin Complex. The hydroxamic acid inhibitors (I-1 and I-2; 1.0 mg) were dissolved in 1 ml of 2H20. The solution was adjusted to p2H 7.6 with trace amounts of 2HCl or NaO2H, divided into two 0.5-ml aliquots, and dried on a SpeedVac system (Savant). The dried inhibitors were dissolved in 100 ,ul of buffer and added to the concentrated enzyme solution. The final p2H was 7.6 ± 0.1.
NMR. The high-resolution one-dimensional and twodimensional 1H-NMR experiments were done at 500.13 MHz on a Bruker (Billerica, MA) AMX FT-NMR spectrometer equipped with an ASPECT X-32 computer. All spectra were recorded at 30°C. Water suppression was achieved by continuous low-power irradiation (1.4 sec) during the relaxation delay with the transmitter frequency set on the H20 resonance. NMR data were acquired in the pure phase-absorption mode with time-proportional phase incrementation (13, 14) . The NMR pulse sequences used for the proton resonance assignments included two-dimensional proton-proton chemical- (21) . A program was written to identify all conformations that satisfied the interproton distance constraints determined by the TR-NOE experiment.
RESULTS AND DISCUSSION
The TR-NOE experiment allows the determination of conformations of loosely bound enzyme inhibitors (Ki inhibitor with the enzyme, where upon spectral irradiation, the cross-relaxation effects between two protons are transferred from the bound state to the free state. Although the size of the enzyme can be large, it is important that the molecular weight of the inhibitor be low. This restriction is due to the necessity to retain fast correlation times for the inhibitor in the free state (Tc < 10-10 sec), producing postitive proton-proton NOE values with a maximum value of 0.5 for small molecules. For large proteins with long correlation times (T-> 10-8 sec), NOE measurements are negative with a maximum magnitude of 1. Hence, binding interactions of a small inhibitor with an enzyme will increase T-for the inhibitor, giving rise to negative NOE peak integrals. These negative NOE values confirm that the inhibitor in question is binding with the enzyme and allow rapid distinction between bound and unbound cross-relaxation effects.
Two stromelysin inhibitors were chosen on the basis of their structural interest and because of their weak binding characteristics. One-dimensional spectra were obtained for each inhibitor in the free state and in the presence of enzyme. Spectra for hydroxamic acid I-1 in the free and bound states are given in Fig. 2 . The spectrum of hydroxamic acid I-1 with stromelysin shows a single set of broadened resonances and a slight change in the chemical shifts, indicative of a fast binding equilibrium between enzyme and inhibitor. Another very sensitive indication of ligand binding with the enzyme can be obtained from selective proton-relaxation measurements (Tisel) (22) . Relaxation time measurements (Tisel) for inhibitor I-1 in both the free state and complexed to stromelysin are given in Table 1 . The data show a dramatic decrease in the spin lattice relaxation times on going from the free to the bound state. This result is not unexpected because slower diffusional motions will affect the spin relaxation (23) .
Two-dimensional NOE spectra were collected for each inhibitor in the presence of stromelysin. A representative TR-NOE spectrum of inhibitor I-1 complexed to stromelysin is shown in Fig. 3 . Each of the cross peaks was integrated, and the corresponding interproton distances for hydroxamic acid I-1 and I-2 were calculated by using Eq. 1, r = [ua/aT]116ra, [1] where Ua is the observed cross-relaxation rate between two ortho phenyl protons and ra is the fixed internuclear distance of 2.5 A. To compensate for errors associated with the integration of experimental data, the NOE cross peaks were classified into three categories: strong (2.0-3.0 A), medium (2.5-3.5 A), and weak (3.0-5.0 A). Thirteen distance constraints were obtained for inhibitor I-1, and eleven distance constraints were obtained for I-2. (Distance constraint tables are available from the authors upon request.)
An extensive conformational search was conducted that generated an ensemble of low-energy conformers for each molecule using the Monte Carlo/energy minimization conformational search procedure. On superimposing the first 10 lowest energy conformations for each inhibitor, one observes a large variation in the conformations that these molecules can adopt. This modeling result suggests that these molecules possess a large degree of flexibility in the free state. NMR spectroscopy provides experimental evidence to corroborate this result. The ROESY spectrum, obtained for each compound in the absence ofenzyme, showed minor sequential ROE cross peaks, with no ROE constraints defining a preferred conformation. Hence, it is likely that these compounds possess a high degree of conformational flexibility in solution.
The enzyme-bound conformations of each inhibitor were obtained by searching all conformers with energies <25 kJ above the global minimum and identifying those conformations that satisfy the interatomic distances determined from the NOE data. An ensemble of structures satisfying the NOE data was collected from hundreds of low-energy conformers. Each set of NOEderived conformers for I-1 and I-2 superimposed with very good agreement; only the conformation of the hydroxamic acid moiety remained undefined, due to the lack of NOE constraints caused by deuterium exchange with the buffer.
The NOE-derived structures for the enzyme-bound inhibitor (I-1) showed the orientation of the methyls of the isobutyl group eclipsed with the aromatic ring. This result was largely due to the interactions between methyl protons e and aromatic protons a and b, and the lack of an observed interaction between protons d and b. Hydroxamic acid I-2 showed an eclipsed wr stacking orientation of its two phenyl rings in the bound state. NOE constraints between protons e and c, as well as f and b, and f and a are responsible for fixing the orientation of the aromatic moieties (Fig. 4) . This ir stacking orientation is not unusual for sulfonamides of this type. X-ray crystallography studies have been reported showing that sulfonamides similar to inhibitor I-2 adopt a Ir stacking orientation in the crystal state (24) .
It should be noted that the mirror images of these bound conformers will also satisfy the NOE constraints. For purposes of clarity, the mirror images will be described as conformational enantiomers. Because neither hydroxamic acid I-1 nor 1-2 possesses a chiral center, these molecules can interconvert to their conformational enantiomers I-1' and I-2', respectively, via bond rotation.
The stromelysin-bound conformational enantiomers I-1 and 1-2 superimposed with excellent agreement (Fig. 5) . The superimposed structure places the isobutyl group in I-1 in the same orientation as the phenyl ring in I-2 and shows a strong hydrophobic clustering for both inhibitors in the bound state. Superimposing the alternative conformational enantiomer, 1-2' with I-1, places the I-2' phenyl ring and g methyl groups outside of the I-1 template boundaries (Fig. 6) . Hence, structural comparison reveals that only one set of enantiomeric conformers should be compatible with the stromelysin-binding site. The correct conformational enantiomers were identified as I-1 and I-2, illustrated in Fig. 5 , based on comparison of these conformers with the conformation of a similar chiral inhibitor bound to stromelysin (N.C.G., unpublished work). These structures thus represent the experimentally determined bioactive conformation of a hydroxamic acid inhibitor bound to stromelysin.
Because no three-dimensional structure of stromelysin was available, thermolysin could be substituted as a template in rational drug design. Thermolysin, a zinc endopeptidase isolated from the thermophile Bacillus thermoproteolyticus, was chosen because its crystal structure is known and because there is evidence suggesting that the active sites of both stromelysin and thermolysin have structural features in common (25) (26) (27) . Examination of thermolysin as a template for design of stromelysin inhibitors revealed some interesting similarities and differences between the two enzymes. Extensive modeling studies were done to determine whether stromelysin inhibitors I-1 and 1-2 could be docked in the thermolysin-binding pocket (28) . The results showed that a conformation similar to I-1' could be modeled into the thermolysin active site, which was consistent with the observed activity of this compound in the thermolysin assay. This molecular modeling result was corroborated by an x-ray structure of the (I-1)-thermolysin complex (M. Grutter, personal communication). Modeling studies ofhydroxamic acid 1-2 in thermolysin, however, showed that no conformation of 1-2 could be favorably accommodated in the active site of the enzyme. Once again these results were consistent with data showing no enzyme inhibition for 1-2 in the thermolysin assay (Table 2) .
Experiments were subsequently done to determine the degree to which stromelysin-bound conformers of I-1 and 1-2 could be accommodated in the thermolysin-binding pocket. As expected, the enantiomeric conformer I-1' docked reasonably well in the active site of thermolysin. This conformer closely matched that obtained from x-ray and modeling studies. The stromelysin-bound conformational enantiomer I-1 (shown in Fig. 5 ), however, experienced large steric violations in the S2' pocket of thermolysin. This result was due to the orientation of the isobutyl group, which occupies the Si' binding pocket in the former case and S2' in the latter (Fig. 7) . Likewise, the enantiomeric conformers I-2 and I-2' could not be accommodated in the thermolysin active site. In this case steric violations in the Si' and S2' binding pockets were largely responsible for the poor fit. These results suggest that the shape and orientation of the Si' and S2' binding pockets must be quite different for stromelysin relative to thermolysin to allow stromelysin to accommodate the enzyme-bound conformations of I-1 and I-2.
On the basis of comparative structural analysis and of the docking studies of the stromelysin inhibitors with thermolysin, one may expect that the S1' and S2' binding pockets possess a different shape and orientation for stromelysin vs. thermolysin. The fact that the conformational enantiomer I-1' was accommodated in the binding pocket of thermolysin suggests that some structural overlap may exist between stromelysin and thermolysin; however, despite any similarities, the overall results show significant differences between the two enzymes. Hence, caution must be exercised when using an enzyme with similar binding characteristics for conformationally restricted drug design. To exploit the use of these structures as templates in the drug-design process, the conformation of I-2 and a similar chiral inhibitor (N.C.G., unpublished work) were transformed into a specific three-dimensional query for use in searching a MACCS-3D version of the CIBA Pharmaceuticals proprietary corporate data base, which contained 260,000 two-dimensional compounds with 470,000 three-dimensional models (29) . (MACCS-3D is available from MDL Information Systems, San Leandro, CA.) Three substructural features were retained: the ir stacked rings, the benzene sulfonyl group, and a generic hydrogen-bond acceptor (or zinc-binding) group. Several three-dimensional query constraints, derived from the inhibitor-bound conformations, were constructed to define the relative location of these substructural features in space. The complete query may be considered as another way of mapping the ligand-binding site of stromelysin. When this query was used to perform a conformationally flexible search of the CIBA data base, 23 compounds were identified for which stromelysin-binding data existed. Of the 23 compounds identified, 5 exhibited stromelysin binding >200 nM, 4 exhibited binding in the range 100-200 nM, and 14 exhibited binding <100 nM. The high success rate of the three-dimensional data base search in identifying tight-binding stromelysin inhibitors served to validate the concept as well as the query itself. In addition, an alternative scaffolding scheme for linking ir stacked rings was uncovered, which was different from that illustrated by hydroxamic acid I-2, thereby providing additional input into the design process.
In conclusion, the enzyme-bound conformations of two hydroxamic acid stromelysin inhibitors have been determined by using the TR-NOE technique. Comparisons of stromelysin inhibitors docked in thermolysin show that the S2' binding pocket possesses a significantly different shape in stromelysin, as well as a different orientation of the S1' pocket relative to S2'. These studies have provided a conformationally restricted template for the design and structural modification of stromelysin inhibitors.
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